February 25, 2022 07:12 AM ESTUpdated March 11, 06:02 AM

Orphazyme runs into another setback as Europe appears unlikely to approve its FDA-rejected drug

The hits just keep on coming for Orphazyme.

Less than a month after its latest CEO announced he will depart in April for another Danish …

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Or­p­hazyme runs in­to an­oth­er set­back as Eu­rope ap­pears un­like­ly to ap­prove its FDA-re­ject­ed drug